Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Exclusion Criteria

• •1. Clinically significant heart disease (NYHA Class III or IV).
• •2. Presence of severe reaction to PPD (purified protein derivative) (\>40 mm induration).
• •3. Prior malignancy within 5 years that has been treated with extensive chemotherapy / radiation therapy and have the potential for immune dysfunction or who have evidence of metastasis at the time of registration.
• •4. Other serious illnesses, e.g., serious infections requiring antibiotics, bleeding disorders, antibiotic use within 5 days of treatment.
• •5. Previous bone marrow or stem cell transplant.
• •6. History of immunodeficiency disease or autoimmune disease.
• •7. Known positive HIV test.
• •8. Chemotherapy, radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
• •9. Concomitant treatment with corticosteroids (within 30 days of enrollment and during treatment), antihistaminic drugs, or nonsteroidal anti-inflammatory drugs (unless chronically used in low doses for prevention of an acute cardiovascular event or pain control). Topical or inhalational steroids are permitted.
• •10. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
• •11. Mental disorders that may compromise the ability to give informed consent and comply with the requirements of the study.
• •12. Lack of availability of the patient for immunological and clinical follow-up assessment.
• •13. Positive urine or serum pregnancy test.